<DOC>
	<DOCNO>NCT01218386</DOCNO>
	<brief_summary>The present study set evaluate efficacy programmation administration estrogen valerate 6 consecutive day . In prospective randomise trial , study impact administration Progynova® 6 , 7,8 9 10 consecutive day luteo-follicular transition period menstrual cycle .</brief_summary>
	<brief_title>Pretreatment With Estradiol Valerate</brief_title>
	<detailed_description>See Section Interventions</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Ganirelix</mesh_term>
	<criteria>&lt; 36 year old day randomisation FSH &lt; 12 ( early follicular phase ) Normal ultrasound scan , i.e . presence ovary , without evidence abnormality within 6 month prior randomisation . Regular menstrual cycle 2135 day , presumed ovulatory . BMI 18 29 ( inclusive ) 1st 2nd trial IVF ICSI ≥ 36 year old day randomisation Endometriosis ≥ grade 3 PCOS Poor responder ( development &lt; 4 follicle previous IVF/ICSI cycle ) Endocrine metabolic abnormality ( pituitary , adrenal , pancreas , liver kidney )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>ICSI</keyword>
	<keyword>GnRH antagonist</keyword>
	<keyword>planning</keyword>
</DOC>